On June 23rd, Dr. Laura Rigon, a member of the laboratory “Diagnosis and Therapy of Lysosomal Disorders“, was awarded the “2° Premio Triennale Hic Labor 2017 – Catergoria Materie Scientifiche e Tecniche” prize for her PhD thesis entitled “Nanotechnologies for CNS drug delivery: therapy for the neurological compartment in the Mucopolisaccharidoses”. The research work was also supported by the Fondazione Cariparo in the framework of the Bando di Ricerca Pediatrica.

Dr Bianca Calì, member of the Inflammation and Angiogenesis Lab directed by prof. Antonella Viola, presented an oral presentation entitled "CXCL12/SDF-1 Modulates the Rheological Properties of the Nucleus of Mouse Neutrophils" to the last “The Chemokine System at the Crossroads of Physiology and Disease” Gordon Conference (June 3 - 8, 2018 - Newry, ME, US) Read more: https://www.grc.org/chemotactic-cytokines-conference/2018/

Dr Bianca Calì, member of the Inflammation and Angiogenesis Lab directed by prof. Antonella Viola, presented an oral presentation entitled "CXCL12/SDF-1 Modulates the Rheological Properties of the Nucleus of Mouse Neutrophils" to the last “The Chemokine System at the Crossroads of Physiology and Disease” Gordon Conference (June 3 - 8, 2018 - Newry, ME, US) Read more: https://www.grc.org/chemotactic-cytokines-conference/2018/

Recruited new researchers, enhanced facilities, appointed the SAB, launched a website On Monday 25th June, the participating partner’s meeting of the Istituto di Ricerca Pediatrica Città della Speranza took place. The 2017 financial statements were approved. Andrea Camporese, CEO, reminded those present of the significant changes made to the statute last year, with the goal of becoming an international reference in its field. The technical board has introduced a new governance model composed of a managing director, a scientific director, a scientific committee and a scientific advisory board. "In addition, to ensure that the Institute is able to concentrate exclusively...

CHICAGO – A new chemotherapy strategy improves cure rates for children with rhabdomyosarcoma (a rare cancer of the muscle tissue) who are at high risk for cancer recurrence. In a randomized phase III clinical trial, adding six months of low-dose maintenance chemotherapy after initial treatment increased the 5-year overall survival rate from 73.7% to 86.5%. Children with rhabdomyosarcoma who are alive at five years are considered cured, as tumor recurrence is very rare. These findings will be presented in ASCO’s Plenary Session, which features four studies deemed to have the greatest potential to impact patient care, out of the more than...

Di cosa parliamo quando nominiamo i cambiamenti climatici? La ricercatrice Elisa Palazzi ha fissato l’attenzione su alcuni aspetti importanti - sette, ma potrebbero essere certamente di più – inerenti le nostre conoscenze sui mutamenti in corso e su quelli attesi, nonché sui loro impatti. Li svelerà mercoledì 30 maggio nella conferenza di chiusura del “Viaggio al centro della scienza”.   Dottoressa Palazzi, lei studia i cambiamenti climatici nelle regioni di montagna. Perché queste ultime sono le maggiori sentinelle di tale fenomeno? Perché rispondono più intensamente e più in fretta ai cambiamenti esterni. Se, globalmente, nell’ultimo secolo e mezzo circa, la...